Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers
| Autor: | Ravali Janagama, Srikrishna V Malayala, Sharanya Peruru, Renuka Ananth Kalyan Kadali |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) myalgia Adverse event Adult medicine.medical_specialty COVID-19 Vaccines Side effect Nausea Health Personnel 030106 microbiology Infectious and parasitic diseases RC109-216 Article 03 medical and health sciences 0302 clinical medicine Internal medicine Pfizer BioNtech Activities of Daily Living medicine Palpitations Humans 030212 general & internal medicine RNA Messenger Adverse effect BNT162 Vaccine Fatigue ComputingMethodologies_COMPUTERGRAPHICS business.industry SARS-CoV-2 COVID-19 General Medicine Emergency department Acceptance Infectious Diseases mRNA vaccine Cross-Sectional Studies Chills BNT162b2 Self Report medicine.symptom business muscle spasm |
| Zdroj: | International Journal of Infectious Diseases International Journal of Infectious Diseases, Vol 106, Iss, Pp 376-381 (2021) |
| ISSN: | 1878-3511 1201-9712 |
| Popis: | Graphical abstract Introduction Concerns are prevailing about the safety and side effects of the BNT162b2 mRNA vaccine for coronavirus disease 2019 (COVID-19). Methods A randomized, cross-sectional study was performed to investigate the side effects of the BNT162b2 vaccine using an independent online questionnaire gathering responses from healthcare workers (HCWs) with detailed review of organ systems. Results Of all HCWs, 87.98% (1245/1415) completed the survey. Of them, 64.5% (803/1245) received the BNT162b2 mRNA vaccine and reported at least one or more symptoms (classified based on organ systems and occurrence rate) post vaccination. Of these, 640/803 (79.7%) were able to continue activities of daily living (ADL), 103/803 (12.83%) had trouble temporarily to perform ADL, 99/803 (12.33%) took time off work temporarily, 20/803 (2.49%) required help from an outpatient provider, 5/803 (0.62%) required help from an emergency department and 2/803 (0.25%) required hospitalization. Despite this, 97.61% intended to have the second dose and 92.9% had already received it. Conclusions Commonly reported symptoms (occurrence in descending order) were soreness, fatigue, myalgia, headache, chills, fever, joint pain, nausea, muscle spasm, sweating, dizziness, flushing, feelings of relief, brain fogging, anorexia, localized swelling, decreased sleep quality, itching, tingling, diarrhoea, nasal stuffiness and palpitations. Despite this, remarkable acceptance for the second dose of the BNT162b2 vaccine was found among HCWs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|